

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumention Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
 (Stock code: 1477)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD
 ON JUNE 29, 2021**

The Board announces that all the resolutions as set out in the Notice were duly passed by the Shareholders as ordinary resolutions by way of poll at the Annual General Meeting.

The board of directors (the “**Board**”) of Ocumention Therapeutics (the “**Company**”) is pleased to announce the poll results of the annual general meeting of the Company (the “**Annual General Meeting**”) held at Taishan Meeting Room, 5th Floor, Want Want Plaza, No. 211 Shimen Yi Road, Jing’an District, Shanghai, the People’s Republic of China on Tuesday, June 29, 2021 at 10:00 a.m..

Reference is made to the Company’s circular (the “**Circular**”) in connection with the Annual General Meeting and notice of the Annual General Meeting (the “**Notice**”) dated May 28, 2021. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The voting results in respect of the resolutions proposed at the Annual General Meeting were as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended December 31, 2020.	439,145,250 (99.999999%)	5 (0.000001%)
2.	(a) To re-elect the following retiring directors of the Company:		
	(i) Dr. Lian Yong CHEN, executive director of the Company	422,512,940 (96.212571%)	16,632,315 (3.787429%)
	(ii) Mr. Ye LIU, executive director of the Company	438,618,650 (99.880084%)	526,605 (0.119916%)

Ordinary Resolutions				Number of Votes (%)	
				For	Against
	(iii)	Dr. Wei LI, executive director of the Company	438,618,650 (99.880084%)	526,605 (0.119916%)	
	(iv)	Ms. Yumeng WANG, non-executive director of the Company	438,477,150 (99.847862%)	668,105 (0.152138%)	
	(b)	To authorise the board of directors of the Company to fix the remuneration of the directors.	439,145,245 (99.999998%)	10 (0.000002%)	
3.		To re-appoint Deloitte Touche Tohmatsu as auditor of the Company and authorise the board of directors of the Company to fix their remuneration.	439,145,250 (99.999999%)	5 (0.000001%)	
4.	(A)	To give a general mandate to the directors of the Company to allot, issue and deal with additional shares not exceeding 20% of the issued share capital of the Company as at the date of this resolution.	379,137,975 (86.744324%)	57,937,280 (13.255676%)	
	(B)	To give a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the issued share capital of the Company as at the date of this resolution.	439,145,250 (99.999999%)	5 (0.000001%)	
	(C)	To extend the authority given to the directors of the Company pursuant to ordinary resolution no. 4(A) to issue shares by adding to the issued share capital of the Company the number of shares repurchased under ordinary resolution no. 4(B).	367,757,980 (84.140654%)	69,317,275 (15.859346%)	
5.	(a)	To authorize the board of directors of the Company to create and issue the Warrants to Alimera.	436,923,250 (99.965222%)	152,005 (0.034778%)	
	(b)	To grant the board of directors a specific mandate to exercise the powers of the Company to allot and issue the Warrant Shares including the adjustment thereof, upon exercise of the Warrants.	437,064,750 (99.997597%)	10,505 (0.002403%)	
	(c)	Any one or more of the directors of the Company be and are hereby authorized to do all such acts and things, to sign and execute such documents or agreements or deed on behalf of the Company and to do such other things and to take all such actions as he/she considers or they consider necessary, appropriate, desirable or expedient for the purposes of giving effect to or in connection with the Warrant Subscription Agreement and all the transactions in relation to the creation and issue of the Warrants and the allotment and issue of the Warrant Shares and to agree to such variation, amendments or waiver or matters relating thereto (excluding any variation, amendments or waiver of such documents or any terms thereof, which are fundamentally and materially different from those as provided for in the Warrant Subscription Agreement and which shall be subject to approval of the shareholders of the Company) as are, in the opinion of any one or more of the directors of the Company, in the interest of the Company and its shareholders as a whole.	437,064,750 (99.997597%)	10,505 (0.002403%)	

Please refer to the Notice for the full text of the resolutions proposed at the Annual General Meeting.

As more than 50% of the votes were cast in favour of each of the above resolutions, all the resolutions were passed as ordinary resolutions at the Annual General Meeting.

The total number of issued Shares as at the date of the Annual General Meeting was 631,205,380 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against all resolutions. There were no Shares entitling the holders to attend and abstain from voting in favour at the Annual General Meeting as set out in rule 13.40 of the Listing Rules. There were no restrictions on any Shareholders casting votes on any of the proposed resolutions at the Annual General Meeting. No person was required under the Listing Rules to abstain from voting on the resolutions proposed at the Annual General Meeting and no party has stated its intention in the Circular to vote against or to abstain from voting the resolutions proposed at the Annual General Meeting.

Computershare Hong Kong Investor Services Limited, the Hong Kong branch share registrar and transfer office of the Company, acted as the scrutineer for counting of votes at the Annual General Meeting.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Executive Director

Hong Kong, June 29, 2021

As of the date of this announcement, the Board comprises Dr. Lian Yong CHEN, Mr. Ye LIU, Dr. Zhaopeng HU and Dr. Wei LI as executive directors, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE, and Mr. Yiran HUANG as independent non-executive directors.